<DOC>
	<DOCNO>NCT01959165</DOCNO>
	<brief_summary>This multi-centre , randomised , double-blind , placebo control , parallel group , Phase II study evaluate efficacy safety 3 dos MEDI7183 , Japanese subject moderate severe UC</brief_summary>
	<brief_title>MEDI7183 Phase 2 Study Japanese Ulcerative Colitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Diagnosis UC establish clinical endoscopic evidence corroborate histopathology report Moderate severe active UC define total Mayo score 6 12 rectosigmoidoscopy score ≥ 2 screening period Demonstrated inadequate response , loss response , intolerance least one immunomodulators Anti TNFα agent . etc . Disease limit rectum Toxic megacolon Crohn 's Disease History subtotal colectomy ileorectostomy colectomy ileoanal pouch , Koch pouch , ileostomy UC Planned bowel surgery within 12 week Visit 2 Stool positive C. difficile toxin screen Primary Sclerosing Cholangitis History gastrointestinal surgery within 8 week Visit 2 Any uncontrolled clinically significant systemic disease Condition disease , opinion investigator would pose risk subject safety interfere study evaluation , procedures completion Subjects positive HBsAg , HBsAb , HBcAb HCVAb serology screen etc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ulcerative Colitis , Japanese , subcutaneously</keyword>
</DOC>